PMID- 25216018
OWN - NLM
STAT- MEDLINE
DCOM- 20151209
LR  - 20211021
IS  - 1755-5949 (Electronic)
IS  - 1755-5930 (Print)
IS  - 1755-5930 (Linking)
VI  - 21
IP  - 4
DP  - 2015 Apr
TI  - Targeting CD36-mediated inflammation reduces acute brain injury in transient, but 
      not permanent, ischemic stroke.
PG  - 385-91
LID - 10.1111/cns.12326 [doi]
AB  - AIMS: The pathology of stroke consists of multiple pro-death processes, and CD36 
      has been suggested as a multimodal target to reduce oxidative stress and 
      inflammation in ischemic stroke. Using CD36-deficient mice and SS-31, a cell 
      permeable tetrapeptide known to down-regulate CD36 pathways, the current study 
      investigated whether targeting CD36 is effective in transient and permanent 
      ischemic stroke. METHODS: Wild-type or CD36-deficient mice were subjected to 
      either 30-min transient or permanent focal ischemic stroke. In parallel, a cohort 
      of mice subjected to either transient or permanent stroke received either vehicle 
      or 5 mg/kg of SS-31. Monocyte chemoattractant protein-1 (MCP-1) and its receptor 
      CCR2, mRNA levels, and infarct volume and percent hemispheric swelling were 
      measured in the postischemic brain. RESULTS: CD36 deficiency or SS-31 treatment 
      significantly attenuated MCP-1 or CCR2 mRNA up-regulation and injury size in the 
      transient ischemic stroke. However, the approaches failed to show the protective 
      effect in permanent ischemic stroke. CONCLUSION: The study revealed that 
      targeting CD36 has a beneficial effect on transient but not permanent focal 
      ischemic stroke. The study thus precludes a generalized strategy targeting CD36 
      in ischemic stroke and suggests careful consideration of types of stroke and 
      associated pathology in developing stroke therapies.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Kim, Eun-Hee
AU  - Kim EH
AD  - Burke-Cornell Medical Research Institute, White Plains, NY, USA; Feil Family 
      Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY, 
      USA.
FAU - Tolhurst, Aaron T
AU  - Tolhurst AT
FAU - Szeto, Hazel H
AU  - Szeto HH
FAU - Cho, Sung-Hee
AU  - Cho SH
LA  - eng
GR  - R01 HL082511/HL/NHLBI NIH HHS/United States
GR  - R01 NS077897/NS/NINDS NIH HHS/United States
GR  - HL82511/HL/NHLBI NIH HHS/United States
GR  - NS07396/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140912
PL  - England
TA  - CNS Neurosci Ther
JT  - CNS neuroscience & therapeutics
JID - 101473265
RN  - 0 (CD36 Antigens)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Ccr2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Oligopeptides)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, CCR2)
RN  - 0 (arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/*immunology/pathology
MH  - Brain Ischemia/drug therapy/*immunology/pathology
MH  - CD36 Antigens/*deficiency/genetics
MH  - Chemokine CCL2/metabolism
MH  - Cohort Studies
MH  - Disease Models, Animal
MH  - Infarction, Middle Cerebral Artery
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Neuroprotective Agents/*pharmacology
MH  - Oligopeptides/*pharmacology
MH  - RNA, Messenger/metabolism
MH  - Random Allocation
MH  - Receptors, CCR2/metabolism
MH  - Stroke/drug therapy/*immunology/pathology
PMC - PMC4362808
MID - NIHMS623276
OTO - NOTNLM
OT  - CD36
OT  - Inflammation
OT  - Permanent focal ischemia
OT  - SS-31
OT  - Transient focal ischemia
COIS- The SS peptides described in this article are licensed for commercial research 
      and development to Stealth Peptides Inc, a clinical stage biopharmaceutical 
      company, in which HHS, SC, and the Cornell Research Foundation have financial 
      interests.
EDAT- 2014/09/13 06:00
MHDA- 2015/12/15 06:00
PMCR- 2014/09/12
CRDT- 2014/09/13 06:00
PHST- 2014/07/09 00:00 [received]
PHST- 2014/08/14 00:00 [revised]
PHST- 2014/08/16 00:00 [accepted]
PHST- 2014/09/13 06:00 [entrez]
PHST- 2014/09/13 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2014/09/12 00:00 [pmc-release]
AID - CNS12326 [pii]
AID - 10.1111/cns.12326 [doi]
PST - ppublish
SO  - CNS Neurosci Ther. 2015 Apr;21(4):385-91. doi: 10.1111/cns.12326. Epub 2014 Sep 
      12.